Close
Novotech
Jabsco PureFlo 21 Single Use

Press Releases

Early diagnosis of bowel cancer in the England – Report Highlights

The importance of national screening Data published by Cancer Research UK and Public Health England’s National Cancer Intelligence Network have reported, for the first time & detected through different healthcare. The stages at which bowel...

Follow-up Data from Two Pivotal Opdivo (nivolumab) Trials Demonstrates Sustained Survival Results in Patients with Previously Treated Squamous Non-Small Cell Lung Cance

European Commission has approved an updated label for Daklinza for the treatment of genotype 3 chronic hepatitis C (HCV). The update allows the use of Daklinza in combination with sofosbuvir for 12 weeks in patients without cirrhosis in all...

Updated Label for Daklinza (daclatasvir) for the 12-week Treatment of Non-cirrhotic Patients with Chronic Hepatitis C Genotype 3 Approved by the European Commission

European Commission has approved an updated label for Daklinza for the treatment of genotype 3 chronic hepatitis C (HCV). The update allows the use of Daklinza in combination with sofosbuvir for 12 weeks in patients without cirrhosis in all...

ALLY-1 Trial Results Show Investigational Daclatasvir-Based Regimen Cures 94% of Post-Liver Transplant Patients with Hepatitis C and Up to 94% of Hepatitis C Patients...

The primary endpoints were successfully met in ALLY-1, a Phase III clinical trial evaluating a 12-week regimen of daclatasvir and sofosbuvir once-daily with ribavirin for the treatment of patients with chronic hepatitis C virus (HCV) with either advanced cirrhosis...

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Non-Squamous Non-Small Cell Lung Cancer Patients

Submission based on positive results of the landmark, global Phase 3 study, CheckMate -057 evaluating overall survival versus standard of care in non-squamous non-small cell lung cancer patients U.S. FDA grants application priority review, and Opdivo Breakthrough Therapy Designation...

Bristol-Myers Squibb to Host Investor Teleconference to Discuss World Conference on Lung Cancer (WCLC) Highlights

Bristol-Myers Squibb Company (NYSE:BMY) will host a teleconference on Tuesday, September 8 at 8 a.m. EDT (6 a.m. MDT) to review data presented at the 16th Annual World Conference on Lung Cancer (WCLC) in Denver, CO. ...

coramaze technologies raises EUR 4.5 million to advance novel transfemoral mitral valve repair system into the clinic

Coramaze technologies GmbH, a German medical device company, is developing themitramaze® valve repair system – a novel concept for transcatheter mitral valve repair (TMVRep) intended for treatment of inoperable patients suffering from severe functional mitral regurgitation (fMR). ...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »